Is PZRXQ or JNJ a better dividend investment in 2026?

PZRXQ currently yields 2000000.00% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: PZRXQ offers higher current income.

What is the dividend yield difference between PZRXQ and JNJ?

PZRXQ has a forward dividend yield of 2000000.00% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 1999997.87 percentage points.

Home › Compare › PZRXQ vs JNJ

PZRXQ vs JNJ: Dividend Comparison 2026

PZRXQ yields 2000000.00% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PZRXQ wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PZRXQ

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full PZRXQ calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — PZRXQ vs JNJ

📍 PZRXQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PZRXQ	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PZRXQ + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PZRXQ pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PZRXQ

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, PZRXQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PZRXQ + JNJ for your $10,000?

PZRXQ: 50%JNJ: 50%

100% JNJ50/50100% PZRXQ

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PZRXQ

No analyst data

Altman Z

-25.0

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PZRXQ buys

JNJ buys

No recent congressional trades found for PZRXQ or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPZRXQJNJ

Forward yield	2000000.00% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$4.879226400974806e+39M	$30.3K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$4,689.40
Total dividends collected	$4.879195005460081e+39M	$15.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: PZRXQ vs JNJ ($10,000, DRIP)

Year	PZRXQ Portfolio	PZRXQ Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$10,592	$272.30	+$200.00M → PZRXQ
2	$3,738,731,768,458	$3,738,517,757,009.35	$11,289	$357.73	+$3738731.76M → PZRXQ
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$12,123	$472.89	+$65315062866.92M → PZRXQ
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$13,141	$629.86	+$1066400830062625.00M → PZRXQ
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$14,408	$846.81	+$16272182796453826560.00M → PZRXQ
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$16,021	$1,151.60	+$2.3205424011366188e+23M → PZRXQ
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$18,122	$1,588.22	+$3.0927990661046884e+27M → PZRXQ
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$20,930	$2,228.20	+$3.8524105697352695e+31M → PZRXQ
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$24,792	$3,191.91	+$4.484688260147987e+35M → PZRXQ
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$30,274	$4,689.40	+$4.879226400974806e+39M → PZRXQ

PZRXQ vs JNJ: Complete Analysis 2026

PZRXQ — Stock

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Full PZRXQ Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this PZRXQ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PZRXQ vs SCHD PZRXQ vs JEPI PZRXQ vs O PZRXQ vs KO PZRXQ vs MAIN PZRXQ vs ABBV PZRXQ vs MRK PZRXQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.